Jaskólski M, Tomasselli A G, Sawyer T K, Staples D G, Heinrikson R L, Schneider J, Kent S B, Wlodawer A
Macromolecular Structure Laboratory, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21702-1201.
Biochemistry. 1991 Feb 12;30(6):1600-9. doi: 10.1021/bi00220a023.
The crystal structure of a complex between chemically synthesized human immunodeficiency virus type 1 (HIV-1) protease and an octapeptide inhibitor has been refined to an R factor of 0.138 at 2.5-A resolution. The substrate-based inhibitor, H-Val-Ser-Gln-Asn-Leu psi [CH(OH)CH2]Val-Ile-Val-OH (U-85548e) contains a hydroxyethylene isostere replacement at the scissile bond that is believed to mimic the tetrahedral transition state of the proteolytic reaction. This potent inhibitor has Ki less than 1 nM and was developed as an active-site titrant of the HIV-1 protease. The inhibitor binds in an extended conformation and is involved in beta-sheet interactions with the active-site floor and flaps of the enzyme, which form the substrate/inhibitor cavity. The inhibitor diastereomer has the S configuration at the chiral carbon atom of the hydroxyethylene insert, and the hydroxyl group is within H-bonding distance of the two active-site carboxyl groups in the enzyme dimer. The two subunits of the enzyme are related by a pseudodyad, which superposes them at a 178 degrees rotation. The main difference between the subunits is in the beta turns of the flaps, which have different conformations in the two monomers. The inhibitor has a clear preferred orientation in the active site and the alternative conformation, if any, is a minor one (occupancy of less than 30%). A new model of the enzymatic mechanism is proposed in which the proteolytic reaction is viewed as a one-step process during which the nucleophile (water molecule) and electrophile (an acidic proton) attack the scissile bond in a concerted manner.
化学合成的1型人类免疫缺陷病毒(HIV-1)蛋白酶与一种八肽抑制剂形成的复合物的晶体结构已在2.5埃分辨率下精修至R因子为0.138。基于底物的抑制剂H-Val-Ser-Gln-Asn-Leu psi [CH(OH)CH2]Val-Ile-Val-OH(U-85548e)在可裂解键处含有一个羟乙烯等排体替代物,据信它模拟了蛋白水解反应的四面体过渡态。这种强效抑制剂的Ki小于1 nM,被开发用作HIV-1蛋白酶的活性位点滴定剂。该抑制剂以伸展构象结合,并与酶的活性位点底部和侧翼形成β折叠相互作用,这些部位构成了底物/抑制剂腔。抑制剂非对映体在羟乙烯插入片段的手性碳原子处具有S构型,并且羟基处于酶二聚体中两个活性位点羧基的氢键距离内。酶的两个亚基通过一个假二元轴相关联,该轴以178度旋转将它们叠加。亚基之间的主要差异在于侧翼的β转角,这两个单体中的构象不同。抑制剂在活性位点具有明确的优先取向,若有任何其他构象,则是次要的(占有率小于30%)。提出了一种新的酶促机制模型,其中蛋白水解反应被视为一个一步过程,在此过程中亲核试剂(水分子)和亲电试剂(一个酸性质子)协同攻击可裂解键。